Oncolytics Biotech Inc. (ONCY)

Oncology Corporate Profile

Stock Performance

2.6300
0.3800

HQ Location

210, 1167 Kensington Crescent NW
Calgary, AB, Canada, T2N 1X7

Company Description

Oncolytics Biotech Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human cancers. The Company explores the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer.

Website: http://www.oncolyticsbiotech.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Reolysin®oncolytic virus1st line metastatic Head & Neck cancerII
Reolysin®oncolytic virus1st line metastatic Pancreatic cancerII
Reolysin®oncolytic virusColorectal cancerII
Reolysin®oncolytic virusMelanomaII
Reolysin®oncolytic virusNon Small Cell Lung Cancer (NSCLC)II
Reolysin®oncolytic virusOvarian cancerII
Reolysin®oncolytic virusSarcomaII
Reolysin®oncolytic virusSquamous cell carcinoma Lung cancerII
Reolysin® (+ paclitaxel and carboplatin)oncolytic virusPancreatic cancerII
Reolysin® (+ gemcitabine)oncolytic virusPancreatic cancerII
Reolysin® (+ paclitaxel and carboplatin)oncolytic virusMelanomaII
Reolysin® (+ paclitaxel and carboplatin)oncolytic virusNon Small Cell Lung Cancer (NSCLC)II
Reolysin® (+ paclitaxel)oncolytic virusOvarian cancerII
Reolysin®oncolytic virus2nd line metastatic GliomaI
Reolysin®oncolytic virusMultiple MyelomaI
Reolysin®oncolytic virusPediatric cancerI
Reolysin®oncolytic virusVarious cancer typesI
Reolysin® (+ cyclophosphamide)oncolytic virusPediatric cancerI
Reolysin® (+ FOLFIRI and bevacizumab)oncolytic virusColorectal cancerI

View additional information on product candidates here »

Source: http://www.oncolyticsbiotech.com

Recent News Headlines

Oncolytics Biotech® Inc. Reports Additional Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer

8/10/2016 04:08 pm

(Yahoo! Finance) Aug 10, 2016 - Oncolytics Biotech Inc. today announced additional data from IND 211, a randomized, Phase II clinical study of REOLYSIN® in patients with non-small cell lung cancer ("NSCLC"). The study enrolled patients with both non-squamous (adenocarcinoma) and squamous cell histology.

Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel Oncolytic Virus Technology

7/28/2016 03:57 pm

(4-traders) July 28, 2016 - Companies plan to advance Western Oncolytics' lead preclinical therapy into human testing; potential combination of WO-12 with Pfizer's oncology pipeline could enhance therapeutic benefit in patients.

Kite Pharma Commends Scientific Advisory Board Members on Awards Received from the American Association of Cancer Research (AACR)

4/19/2016 02:03 pm

(Kite Pharma) Apr 18, 2016 - Antoni Ribas, M.D., Ph.D. and Ronald Levy, M.D. recognized for their major contributions to cancer research.

Medivation Said to Have Rebuffed Sanofi Takeover Approach

4/13/2016 11:03 am

(Bloomberg) Apr 12, 2016 - Medivation Inc. rebuffed a recent takeover approach from French drugmaker Sanofi, which is pursuing the U.S. company to expand its cancer treatment business, according to people familiar with the matter.

Oncolytics Biotech® Inc. Reports Data from Randomized Phase 2 Study of REOLYSIN® in Ovarian Cancer

3/22/2016 04:41 pm

(Oncolytics Biotech) Mar 21, 2016 - Oncolytics Biotech® Inc. today announced an update for a randomized Phase II clinical trial of its lead product, REOLYSIN®, in combination with paclitaxel in patients with ovarian cancer (GOG-0186H). The study is being sponsored by the US National Cancer Institute ("NCI").

Oncolytics Biotech® Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer

1/19/2016 05:50 pm

(PipelineReview.com) Jan 19, 2016 - Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA®) in combination with REOLYSIN® (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).

Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Published in New England Journal of Medicine

6/2/2015 04:03 pm

(MarketWatch) June 2, 2015 - Bristol-Myers Squibb Company and AbbVie today announced that results from an interim analysis of its Phase III, randomized, open-label ELOQUENT-2 trial were published in the June 2 online edition of the New England Journal of Medicine.

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric Cancer

5/6/2015 03:26 pm

(TheStreet) May 6, 2015 - Oncolytics Biotech Inc. today announced that the FDA has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN®, for the treatment of gastric cancer.

Oncolytics Biotech Receives EMA Orphan Drug Designation for REOLYSIN

4/30/2015 05:27 pm

(StreetInsider) Apr 29, 2015 - Oncolytics Biotech announced that the European Medicines Agency ("EMA") has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer.

Celldex Reports Positive Phase II EMERGE Trial of Glembatumumab Vedotin to Treat Breast Cancer

4/7/2015 12:00 pm

(Pharmaceutical Business Review) Apr 7, 2015 - Celldex Therapeutics has reported positive data from the Phase II EMERGE trial of glembatumumab vedotin, an antibody-drug conjugate, in patients with metastatic breast cancer.

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Cancer of the Fallopian Tube

3/2/2015 06:06 pm

(CNBC) Mar 2, 2015 - Oncolytics Biotech® Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of cancer of the fallopian tube.

Oncolytics Biotech® Inc. Announces Completion Of Enrollment In Randomized Phase II Colorectal Cancer Study

2/18/2015 06:50 pm

(TheStreet) Feb 18, 2015 - Oncolytics Biotech® Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN® in patients with advanced or metastatic colorectal cancer (IND 210).

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Pancreatic Cancer

2/17/2015 06:33 pm

(Yahoo! Finance) Feb 17, 2015 - Oncolytics Biotech® Inc. today announced that the FDA has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian Cancer

2/11/2015 06:07 pm

(TheStreet) Feb 11, 2015 - Oncolytics Biotech® Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of ovarian cancer.

Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study

9/17/2014 05:09 pm

(Yahoo! Finance) Sept 16, 2014 - Oncolytics Biotech® Inc. today announced overall and KRAS-mutated patient data from a two-arm randomized phase 2 study of carboplatin, paclitaxel plus REOLYSIN® (test arm) versus carboplatin and paclitaxel alone (control arm) in the first line treatment of patients with recurrent or metastatic pancreatic cancer (NCI-8601).

Surgery Prices Are Elusive: 13-fold Price Difference Among U.S. Hospitals for Prostate Cancer Surgery

6/10/2014 06:02 am

(Iowa Now/University of Iowa) June 9, 2014 - A University of Iowa study shows a wide range in the prices that US hospitals charge for prostate-cancer surgery, varying by region and by academic or nonacademic centers.

ASCO Statement on President Obama's FY 2015 Budget Proposal

3/5/2014 11:04 am

(ASCO) Mar 4, 2014 - "This afternoon, President Obama released his proposed budget for fiscal year 2015. Among several cost-cutting measures designed to preserve Medicare solvency is a proposal to reduce reimbursement for life-sustaining cancer drugs.”

Cortice Announces Enrollment of a Phase 2 Trial Evaluating TPI 287 Plus Avastin for Treatment of Recurrent Glioblastoma Naive to Prior Anti-Angiogenic Therapy

1/9/2014 10:05 am

(StreetInsider) Jan 9, 2014 - Cortice Biosciences, Inc. announced today that enrollment has begun in the first stage of a Phase 2 open-label trial designed to evaluate the safety and efficacy of the Company's lead drug candidate, TPI 287, in combination with standard-of-care Avastin® (bevacizumab) for treatment of patients with recurrent glioblastoma (GBM) who have not received prior anti-angiogenic treatment for their disease (clinicaltrials.gov ID: NCT01933815).

Karyopharm Therapeutics Presents Promising Data for Selinexor, an Oral, First-in-Class Selective Inhibitors of Nuclear Export (SINE) Compound, in Hematologic Malignancies at 2013 ASH Annual Meeting

12/9/2013 06:02 pm

(Benzinga) Dec 8, 2013 - Karyopharm Therapeutics Inc. today announced the oral presentation of clinical data from an ongoing Phase 1 clinical trial of its lead oral SINE compound, Selinexor (KPT-330), in patients with relapsed and/or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) at ASH.

HIV Virus Returns After Cure Hope Rose

12/6/2013 12:00 pm

(Boston Globe) Dec 6, 2013 - Boston researchers are reporting the return of the HIV virus in two patients who had become virus-free after undergoing bone marrow transplants, dashing hopes of a possible cure that had generated widespread excitement.

Oncolytics Biotech Shades Truth on Failed Cancer Study

11/21/2013 05:25 pm

(The Street) Nov 21, 2013 – There are too many red flags to count in the way Oncolytics Biotech spins results from the Reolysin head and neck cancer study.

Oncolytics Biotech Shades Truth on Failed Cancer Study

11/21/2013 11:02 am

(The Street) Nov 21, 2013 – There are too many red flags to count in the way Oncolytics Biotech spins results from the Reolysin head and neck cancer study.

Oncolytics's Reolysin Shows 92% Tumor Shrinkage

9/9/2013 04:53 pm

(Wall Street Journal) Sep 9, 2013 - Oncolytics Biotech Inc. said final results from a midstage study examining how tumors respond to its lead product candidate Reolysin in patients having squamous cell carcinoma of the lung were positive.

Oncolytics's Reolysin Shows 92% Tumor Shrinkage

9/9/2013 11:05 am

(Wall Street Journal) Sep 9, 2013 - Oncolytics Biotech Inc. said final results from a midstage study examining how tumors respond to its lead product candidate Reolysin in patients having squamous cell carcinoma of the lung were positive.

CMS Steps In to Settle Gamma Knife-Varian Fight

7/11/2013 11:03 am

(Wall Street Journal/Washington Wire blog) July 10, 2013 - The Centers for Medicare and Medicaid Services has proposed a new rule that would effectively put to rest a provision inserted into last year’s fiscal cliff bill by Senate Majority Leader Harry Reid (D., Nev.) to help a U.S. company.

Oncolytics Cancer Drug Meets Mid-Stage Trial Goal, Shares Rise

5/22/2013 05:10 pm

(Reuters) May 22, 2013 - Oncolytics Biotech Inc said preliminary data from a mid-stage trial showed that its cancer drug, Reolysin, met the main goal of reducing the size of tumors in patients with metastatic melanoma, a type of skin cancer.

Oncolytics Cancer Drug Meets Mid-Stage Trial Goal, Shares Rise

5/22/2013 12:01 pm

(Reuters) May 22, 2013 - Oncolytics Biotech Inc said preliminary data from a mid-stage trial showed that its cancer drug, Reolysin, met the main goal of reducing the size of tumors in patients with metastatic melanoma, a type of skin cancer.

Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech

4/5/2013 05:15 pm

(TheStreet) Apr 5, 2013 - Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech

4/5/2013 12:01 pm

(TheStreet) Apr 5, 2013 - Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Oncolytics Lung Cancer Drug Effective in Mid-Stage Trial, Shares Up

3/28/2013 04:39 pm

(Yahoo! News/Reuters) Mar 28, 2013 - Oncolytics Biotech Inc said its experimental lung cancer drug was found to be more effective in a mid-stage trial study, sending its shares up more than 10 percent.

Oncolytics Lung Cancer Drug Effective in Mid-Stage Trial, Shares Up

3/28/2013 11:03 am

(Yahoo! News/Reuters) Mar 28, 2013 - Oncolytics Biotech Inc said its experimental lung cancer drug was found to be more effective in a mid-stage trial study, sending its shares up more than 10 percent.

Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta

3/1/2013 05:34 pm

(TheStreet) Mar 1, 2013 - This week's Biotech Stock Mailbag covers questions about Ziopharm Oncology, Oncolytics Biotech and the competition between GlaxoSmithKline and Sarepta Therapeutics to develop new Duchenne Muscular Dystrophy drugs.

Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta

3/1/2013 11:03 am

(TheStreet) Mar 1, 2013 - This week's Biotech Stock Mailbag covers questions about Ziopharm Oncology, Oncolytics Biotech and the competition between GlaxoSmithKline and Sarepta Therapeutics to develop new Duchenne Muscular Dystrophy drugs.

Oncolytics Sees Positive Results From Reolysin Study; Shares Up

2/8/2013 03:04 pm

(Wall Street Journal) Feb 8, 2013 - Oncolytics Biotech Inc. said results were positive from a mid-stage U.S. trial examining the use of its lead product candidate Reolysin in helping shrink tumors.

Oncolytics Sees Positive Results From Reolysin Study; Shares Up

2/8/2013 09:00 am

(Wall Street Journal) Feb 8, 2013 - Oncolytics Biotech Inc. said results were positive from a mid-stage U.S. trial examining the use of its lead product candidate Reolysin in helping shrink tumors.

Oncolytics Details Broader Use for Reolysin

1/28/2013 06:49 pm

(Yahoo! Finance/ Associated Press) Jan 28, 2013 - Shares of Oncolytics Biotech Inc. climbed Monday after the drug developer said its lead product Reolysin may have a broader use as a potential cancer treatment.

Oncolytics Details Broader Use for Reolysin

1/28/2013 12:04 pm

(Yahoo! Finance/ Associated Press) Jan 28, 2013 - Shares of Oncolytics Biotech Inc. climbed Monday after the drug developer said its lead product Reolysin may have a broader use as a potential cancer treatment.

Oncolytics Treatment for Head and Neck Cancers Shows Positive Results

12/13/2012 06:13 pm

(Wall Street Journal) Dec 13, 2012 - Oncolytics Biotech Inc.'s lead product candidate Reolysin showed positive results in initial data from a Phase III study of patients with head and neck cancers.

Oncolytics Treatment for Head and Neck Cancers Shows Positive Results

12/13/2012 12:01 pm

(Wall Street Journal) Dec 13, 2012 - Oncolytics Biotech Inc.'s lead product candidate Reolysin showed positive results in initial data from a Phase III study of patients with head and neck cancers.

Oncolytics Biotech® Inc. Completes Patient Enrollment in U.S. Phase II Clinical Trial Investigating REOLYSIN® in Combination with Gemcitabine in Patients with Advanced or Metastatic Pancreatic Cancer

10/25/2012 04:57 pm

(BizJournals) Oct 24, 2012 - Oncolytics Biotech Inc. today announced that it has completed patient enrollment in its U.S. Phase II clinical trial using intravenous administration of REOLYSIN in combination with gemcitabine (Gemzar®) in patients with advanced or metastatic pancreatic cancer (REO 017).

Oncolytics Biotech® Inc. Completes Patient Enrollment in U.S. Phase II Clinical Trial Investigating REOLYSIN® in Combination with Gemcitabine in Patients with Advanced or Metastatic Pancreatic Cancer

10/25/2012 11:05 am

(BizJournals) Oct 24, 2012 - Oncolytics Biotech Inc. today announced that it has completed patient enrollment in its U.S. Phase II clinical trial using intravenous administration of REOLYSIN in combination with gemcitabine (Gemzar®) in patients with advanced or metastatic pancreatic cancer (REO 017).

Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Squamous Cell Lung Cancer Clinical Trial

9/13/2012 05:04 pm

(TucsonNewsNow.com) Sept 13, 2012 - Oncolytics Biotech Inc. today announced preliminary results from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 021).

Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Squamous Cell Lung Cancer Clinical Trial

9/13/2012 12:00 pm

(TucsonNewsNow.com) Sept 13, 2012 - Oncolytics Biotech Inc. today announced preliminary results from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 021).

Oncolytics Expands Enrollment For Head & Neck Cancer Study In Two Distinct Groups

9/12/2012 04:44 pm

(RTT News) Sept 12, 2012 - Oncolytics Biotech Inc. Wednesday said it plans to expand enrollment in the first stage of its Phase III trial of Reolysin in combination with carboplatin and paclitaxel for the treatment of head and neck cancers or REO 018.

Oncolytics Expands Enrollment For Head & Neck Cancer Study In Two Distinct Groups

9/12/2012 11:04 am

(RTT News) Sept 12, 2012 - Oncolytics Biotech Inc. Wednesday said it plans to expand enrollment in the first stage of its Phase III trial of Reolysin in combination with carboplatin and paclitaxel for the treatment of head and neck cancers or REO 018.

Lack of Sleep Found to be a New Risk Factor for Aggressive Breast Cancers

8/27/2012 11:04 am

(University Hospitals) Aug 24, 2012 - Lack of sleep is linked to more aggressive breast cancers, according to new findings published in the August issue of Breast Cancer Research and Treatment by physician-scientists from University Hospitals Case Medical Center’s Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University.

Biotech Stock Mailbag: Oncolytics, Sarepta, Delcath, Peregrine

8/24/2012 03:59 pm

(The Street) Aug 24, 2012 - Forgive me, for I have sinned. It's been three weeks since my last Biotech Stock Mailbag. Vacation is over, so let's get back to your questions.

Biotech Stock Mailbag: Oncolytics, Sarepta, Delcath, Peregrine

8/24/2012 10:05 am

(The Street) Aug 24, 2012 - Forgive me, for I have sinned. It's been three weeks since my last Biotech Stock Mailbag. Vacation is over, so let's get back to your questions.

ARIAD Announces Initiation of Randomized Phase 3 Trial of Ponatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia

7/27/2012 11:00 am

(TheStreet) July 27, 2012 - ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).